This study explores how changes in the respiratory microbiome relate to systemic inflammation in COPD patients. It highlights correlations between bacterial abundance, eosinophilic markers, and airflow limitation severity.
Explore Treatable Traits model for chronic airway diseases like asthma and COPD in primary care. Learn about seven key traits — airflow obstruction, eosinophilic inflammation, adherence, inhaler technique, smoking, low BMI/obesity and anxiety and depression — that guide personalized care.
This study investigates telomere length (TL) in bronchiectasis patients, comparing them to COPD patients and healthy controls. Findings show no significant TL reduction in bronchiectasis compared to controls, but a trend towards shorter TL in idiopathic cases. Further research is needed to understand TL’s role in bronchiectasis.
Explore the complex pathophysiology of bronchiectasis, including airway infection, chronic inflammation, and mucociliary dysfunction. Learn how genomic approaches, proteomics, and epigenomics offer new insights into disease endotypes and patient stratification for improved therapies. Discover the role of trained innate immunity in complementing current models.
Explore the metabolic changes in COPD patients, highlighting the influence of aging and sex, with pronounced effects in males. Discover how COPD affects protein metabolism and energy production, emphasizing early aging’s impact.
Explore how systemic inflammation differs between brain-dead (DBD) and circulatory-dead (DCD) lung donors and its impact on primary graft dysfunction (PGD) and mortality in lung transplant recipients.
Aspergillus-associated disorders in bronchiectasis, based on data from the EMBARC Registry. ABPA, AS, and AB: Impact on disease severity, diagnostic criteria efficacy, etc.
Marked differences in peripheral blood immune cell gene expression were observed between bronchiectasis patients and healthy controls.
Transcriptomic changes were associated with disease severity and airway inflammation identifying potential novel biomarkers and therapeutic targets.
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
In the general population Persistent Airflow Obstruction (PAO) was largely mild but there are significant phenotypic differences between young and old individuals with PAO
